Related Experiment Video
Updated: Mar 13, 2026
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension
Yasuhiko Matsumori1, Krisztian Nagy2, Akihiro Takahashi3
1Sendai Headache and Neurology Clinic, Sendai, Miyagi, Japan.
Introduction:
Atogepant is an oral calcitonin gene-related peptide receptor antagonist approved in the USA, EU, and Japan for the preventive treatment of migraine in adults. We evaluated the long-term safety, efficacy, and functional outcomes of atogepant for the preventive treatment of migraine in Japanese participants.
Methods:
This open-label, 52-week, long-term safety extension study evaluated atogepant 60 mg once daily for the preventive treatment of migraine in Japanese participants. The study enrolled participants with chronic migraine (CM) who completed the phase 3 PROGRESS trial and de novo participants with episodic migraine (EM). The primary objective was the safety and tolerability of atogepant. Efficacy and functional outcomes were exploratory endpoints.
Results:
Of 204 Japanese participants screened, 186 were enrolled and included in the safety population (CM, n = 155; EM, n = 31) and 180 in the modified intent-to-treat population (CM, n = 150; EM, n = 30). Treatment-emergent adverse events (TEAEs) occurred in 88.7% of participants. TEAEs occurring ≥ 10% were pyrexia (29.0%), nasopharyngitis (16.1%), and constipation (11.3%). Concurrent COVID-19 vaccination attributed to several TEAEs, including pyrexia. Serious TEAEs occurred in 3.8% of participants and none were considered related to atogepant by the investigator. TEAEs leading to discontinuation occurred in 4.8% of participants. Alanine aminotransferase and/or aspartate aminotransferase ≥ 3 × the upper limit of normal occurred in 4.8% of participants; none met criteria for Hy's law. The least squares mean change from baseline in monthly migraine days was - 6.4 days in PROGRESS CM completers and - 3.4 days in de novo EM participants at weeks 1-4 and was consistent over 52 weeks. Similar improvements were observed for the other efficacy and functional outcomes.
Conclusion:
The safety profile of atogepant in Japanese participants was consistent with the known safety profile in the global population. No new safety signals were identified. Improvements in efficacy and functional outcomes persisted over 52 weeks.
Trial Registration:
NCT04437433; https://clinicaltrials.gov/study/NCT04437433.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
01:26Coronary Artery Disease IV: Preventive Measures
01:15Bioavailability Study Design: Healthy Subjects Versus Patients